Survival with combined heart failure and kidney failure ranges from weeks to many years, depending on how advanced each condition is, what treatments are available, and the individual’s overall health. When researchers have tracked patients with severe versions of both diseases, median survival has been as short as about three months in the worst cases and several years in less advanced ones. The enormous spread in those numbers reflects the reality that “kidney failure plus heart failure” is not a single diagnosis but a spectrum, and the answer changes dramatically based on where someone falls on it.
Why Heart and Kidney Failure Amplify Each Other
The heart and kidneys are locked in a feedback loop. When the heart pumps less effectively, blood pressure in the kidneys drops, and the kidneys respond by retaining salt and water to compensate. That extra fluid forces the heart to work even harder, which damages it further. Meanwhile, when the kidneys fail, fluid and waste products build up, raising blood pressure and inflaming the blood vessels that feed the heart. Doctors call this two-way deterioration cardiorenal syndrome, and it encompasses several patterns in which dysfunction in one organ triggers or worsens dysfunction in the other.1PubMed. Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association
The damage is not purely mechanical. The body’s stress-response systems, including the hormonal pathway that regulates salt and blood pressure and the sympathetic “fight or flight” nervous system, stay chronically activated. That sustained activation drives inflammation, oxidative damage to cells, anemia, and a buildup of uremic toxins the kidneys can no longer clear.2Biomolecules. The Heart–Kidney Axis in Heart Failure and Chronic Kidney Disease: Mechanisms, Mediators, and Therapeutic Implications Each of these problems makes the other worse, which is why the combination of heart failure and kidney failure is so much more dangerous than either condition alone.
What the Survival Numbers Look Like
Putting a single number on life expectancy is misleading because the range is vast. A few anchor points from the research help illustrate the spectrum.
At the severe end, a study of heart failure patients whose kidney function deteriorated to the point of needing dialysis found a median survival of just 95 days. The mean was longer, about 15 months, because a small number of patients whose kidney function partially recovered lived considerably longer and pulled the average up.3PubMed. Prognosis in patients with congestive heart failure and subacute renal failure treated with hemodialysis That study captures a particularly grim scenario: advanced heart failure combined with dialysis-dependent kidney failure.
For less extreme cases, a large European registry study found that chronic kidney disease significantly increased the risk of death in heart failure patients across all subtypes of heart failure. The hazard was roughly 50 percent higher in patients whose hearts pumped poorly compared to those without kidney disease, and about 30 percent higher even in patients whose hearts pumped normally but still had heart failure symptoms.4PubMed. Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid-range, and reduced ejection fraction In other words, kidney disease makes the prognosis worse regardless of the specific type of heart failure, but it hits hardest when the heart’s pumping ability is most impaired.
During hospital stays for acute flare-ups, the picture also worsens as kidney disease advances. A national cohort study of patients hospitalized with heart failure and cardiorenal syndrome found that those with the most advanced kidney disease had higher in-hospital mortality and were readmitted within 30 days at nearly triple the rate of patients with early-stage kidney disease.5PubMed. Clinical outcomes and 30-day readmissions for heart failure with reduced ejection fraction with cardiorenal syndrome: A National Cohort Study Acute episodes of worsening kidney function during a heart failure hospitalization are also tied to longer hospital stays, more need for blood-pressure-supporting medications, and higher six-month mortality and readmission rates.6PubMed Central. Unraveling Acute Cardiorenal Syndrome: Predictors and Consequences in Acute Heart Failure
How Medical Treatment Shifts the Timeline
The standard drugs for heart failure become trickier to use when the kidneys are also failing, but they remain critically important. Many of the medications that protect the heart work partly through the kidneys, and managing both organs simultaneously is one of the biggest challenges doctors face.
Diuretics, the water pills that reduce fluid overload, are the first line of defense during acute episodes. High-dose intravenous loop diuretics can promote decongestion across the spectrum of kidney dysfunction, though the body often develops resistance to them over time, requiring combination strategies that target different parts of the kidney’s filtering system.7PubMed Central. Systematic Review on the Management of Diuretic Resistance in Acute Heart Failure across the Spectrum of Kidney Disease In patients with advanced kidney disease, diuretic resistance is a particularly stubborn problem, and alternatives like ultrafiltration, a mechanical method of removing excess fluid, sometimes become necessary.8PubMed Central. Decongestion in patients with advanced chronic kidney disease coexisting with heart failure
SGLT2 inhibitors, a class of drugs originally designed for diabetes, have become a game-changer for cardiorenal patients. They work through multiple routes: lowering pressure inside the kidney’s filtering units, reducing fluid retention, improving how the heart uses fuel, and stimulating red blood cell production that improves oxygen delivery throughout the body.9PubMed Central. Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function Large trials have shown benefits in heart failure and kidney disease independently, and doctors now use them widely in patients who have both.
Blood-pressure medications that block the body’s salt-retaining hormone system, such as ACE inhibitors and ARBs, present a genuine dilemma in advanced kidney disease. A trial in patients with very advanced kidney disease found no clear benefit to stopping these medications, with rates of reaching dialysis and cardiovascular events looking similar whether patients continued or discontinued the drugs.10PubMed. Renin-Angiotensin System Inhibition in Advanced Chronic Kidney Disease Meanwhile, a separate analysis found that starting these medications in advanced kidney disease was associated with about a third lower risk of progressing to the point of needing dialysis.11American College of Cardiology. Risk of Initiating ACE Inhibitors/ARBs in Advanced CKD The evidence suggests that these drugs remain beneficial for most patients even as kidney function declines, though decisions are highly individual.
Dialysis When Both Organs Are Failing
When kidney failure progresses to end-stage and dialysis becomes unavoidable, the choice of dialysis method matters for heart failure patients. A study comparing hemodialysis (where a machine filters the blood several times a week) to peritoneal dialysis (where fluid is cycled through the abdomen at home) found a meaningful survival difference. Patients on hemodialysis had a median survival of about 37 months, compared to about 20 months for those on peritoneal dialysis, and this gap held after adjusting for confounders like age, disease severity, and remaining kidney function.12PubMed. Survival advantage of hemodialysis relative to peritoneal dialysis in patients with end-stage renal disease and congestive heart failure
The reason for the difference is not entirely settled, but hemodialysis removes fluid more aggressively in a single session, which may better manage the congestion that is so dangerous in heart failure. Peritoneal dialysis is gentler and more gradual, which is usually an advantage in kidney-only patients, but the slower fluid removal may leave heart failure patients chronically overloaded. This is one of those areas where the right choice for a kidney patient and the right choice for a heart-and-kidney patient diverge.
Transplant and Mechanical Devices
For patients who are healthy enough to be candidates, transplantation offers the best long-term outcomes. Simultaneous heart-kidney transplantation, where both organs are replaced in a single surgery, has been performed with increasing frequency. A meta-analysis of its long-term results found overall patient survival of about 81 percent at one year and roughly 71 percent at five years.13Transplant International. Simultaneous Heart and Kidney Transplantation: A Systematic Review and Proportional Meta-Analysis of Its Characteristics and Long-Term Variables A separate registry study comparing simultaneous transplant to heart transplant alone found that the combined procedure offered better long-term survival, with five-year survival of about 71 percent for simultaneous recipients versus 64 percent for heart-only recipients.14PubMed Central. Survival Benefit of Heart-Kidney Versus Heart Transplant With or Without Delayed Kidney Transplant
Left ventricular assist devices (LVADs), mechanical pumps implanted in the chest to help a failing heart, are another option, but kidney function heavily influences outcomes. A systematic review found that patients with impaired kidney function who received LVADs had more than double the risk of death compared to those with normal kidneys.15PubMed Central. Impact of Renal Dysfunction on Outcomes after Left Ventricular Assist Device: A Systematic Review For patients whose kidneys had failed completely before LVAD placement, the outlook was far worse: median survival was just 16 days, compared to nearly six years for LVAD recipients without end-stage kidney disease. Most of the deaths in the kidney-failure group occurred within the first 60 days after surgery.16JAMA Internal Medicine. Outcomes Associated With Left Ventricular Assist Devices Among Recipients With and Without End-stage Renal Disease The implication is stark: an LVAD can extend life for years in many heart failure patients, but if the kidneys have already reached end-stage, the device alone is unlikely to help.
When the Goal Shifts to Comfort
Not every patient is a candidate for transplant or aggressive intervention, and many with advanced dual-organ failure eventually reach a point where the focus shifts from extending life to improving its quality. Palliative care, which manages symptoms and supports decision-making, is relevant much earlier than most people assume. Guidelines emphasize that palliative principles can guide care throughout the disease course, not just in the final weeks, and that decisions about when to start, continue, or stop aggressive treatments like dialysis should involve honest conversations about prognosis and goals.17PubMed. Palliative Care Approach to Chronic Diseases: End Stages of Heart Failure, Chronic Obstructive Pulmonary Disease, Liver Failure, and Renal Failure
Breathlessness is one of the most distressing symptoms in end-stage heart failure, and it can be especially difficult to treat when kidney failure limits the drugs that can be used safely. A small case series found that oxycodone significantly reduced breathlessness scores in end-stage heart failure patients who also had chronic kidney disease, dropping symptom severity from a median of 9 out of 10 to about 2.5, without causing dangerous drops in blood pressure or breathing rate.18PubMed Central. Safety and efficacy of oxycodone for refractory dyspnea in end-stage heart failure patients with chronic kidney disease: a case series of eight patients That is a small study, but it illustrates a broader point: effective symptom relief exists even at the most advanced stages, and it does not have to mean giving up.
How Sex and Demographics Shape Outcomes
The cardiorenal syndrome does not look the same in everyone. A registry of chronic ambulatory heart failure patients found distinct patterns by sex. Women with combined heart and kidney disease were more likely to have preserved heart-pumping function, more advanced kidney disease, anemia, and signs of fluid congestion. Men were more likely to have reduced pumping function, a history of coronary artery disease, high blood pressure, irregular heart rhythms, and dangerous potassium levels.19PubMed. Sex differences in Cardiorenal Syndrome: Insights from CARDIOREN Registry These are not just academic curiosities; they affect which treatments work best and how aggressively each condition should be managed.
Preclinical research has begun to explain why these sex differences exist at a biological level. In a mouse model of heart failure following a heart attack, male mice showed significantly reduced kidney filtration and developed resistance to loop diuretics, while female mice maintained normal kidney function and normal diuretic response despite developing comparably reduced heart function.20Physiology. Sex Differences in a Preclinical Model of Type II Cardiorenal Syndrome with Loop Diuretic Resistance If these findings translate to humans, they could help explain why women tend to present with more kidney disease yet may have different protective mechanisms at play.
Racial and ethnic disparities are also significant. An analysis of U.S. mortality trends from 2011 to 2020 found that non-Hispanic Black individuals faced a higher risk of cardiorenal-related death compared to other racial and ethnic groups, a disparity driven by a complex mix of higher rates of diabetes and hypertension, differences in access to healthcare, and a documented history of racial bias in kidney function measurement that has led to differential treatment.21PubMed Central. Demographic trends of cardiorenal and heart failure deaths in the United States, 2011–2020 Separately, data from the UK Biobank showed that low socioeconomic status roughly doubled the risk of developing overlapping heart, kidney, and metabolic diseases, and increased the risk of progressing from one of these conditions to having multiple.22JACC: Advances. Cardiometabolic Associations of Socioeconomic Status With Cardiorenal Metabolic Multimorbidity: Evidence From the UK Biobank Cohort
Blood Tests That Help Predict Individual Outcomes
Because the range of possible survival is so wide, doctors rely on biomarkers to get a more personalized picture. The two most commonly used are creatinine, a waste product that rises as kidney function drops, and NT-proBNP, a hormone fragment released when the heart is under strain. Machine learning models using these two markers have shown promise in predicting mortality in heart failure patients with kidney involvement.23Nephrology Dialysis Transplantation. Machine learning-based assessment of serum creatinine and NT-proBNP levels for predicting mortality in patients with heart failure and kidney injury
However, interpreting these markers gets complicated when both organs are failing. NT-proBNP, which is normally a reliable signal that the heart is struggling, is cleared more slowly when the kidneys are not working well. That means levels can be misleadingly high. European guidelines recommend raising the diagnostic threshold for NT-proBNP by about 35 percent when kidney filtration is severely reduced, to avoid falsely diagnosing heart failure flare-ups.24European Journal of Heart Failure. Diagnostic reliability of BNP and NT-proBNP in acute heart failure amidst sepsis and chronic kidney disease Even with adjusted cutoffs, research in kidney disease patients suggests the optimal thresholds may need to be substantially higher, potentially more than double the standard values.25Pakistan Heart Journal. Optimizing NT-proBNP and Left Ventricular Filling Pressure for Accurate Diagnosis of Acute Decompensated Heart Failure in Chronic Kidney Disease Patients
Newer biomarkers are beginning to offer additional insight. A meta-analysis of renal biomarkers in heart failure found that high levels of cystatin C, a marker of kidney filtering ability, carried about a 60 percent higher risk of death compared to low levels. An even more striking signal came from NGAL, a protein that rises quickly when the kidneys are acutely injured: the highest levels were associated with nearly three times the risk of death and about four times the risk of the combined outcome of death or hospitalization for heart failure.26ScienceDirect / JACC: Advances. Renal Biomarkers in Heart Failure: Systematic Review and Meta-Analysis These markers are not yet standard in everyday clinical practice, but they are moving in that direction and may eventually help doctors intervene earlier when the kidney-heart spiral is accelerating.
The Emotional Weight of Dual-Organ Failure
Living with both heart and kidney failure takes a psychological toll that often goes unrecognized. A preliminary study comparing patients with cardiorenal syndrome to those with heart failure alone found that depressive symptoms were significantly worse in the cardiorenal group, even though general cognitive function and overall quality-of-life scores were similar between the two groups.27MDPI. Comparison of Cardiorenal Syndrome and Heart Failure: A Preliminary Study of Clinical, Cognitive, and Emotional Aspects Anxiety also trended higher in the cardiorenal patients, though the difference did not quite reach statistical significance in that small sample.
Depression in this population is not just an understandable reaction to illness; it is a clinical problem that worsens outcomes. Depressed patients are less likely to take medications consistently, attend dialysis sessions, or follow dietary restrictions, all of which directly affect survival. Screening for depression and offering treatment should be a routine part of cardiorenal care, not an afterthought reserved for patients who happen to mention it.
What Sodium and Fluid Restriction Actually Do
Patients with heart failure are almost universally told to limit salt and fluids, and adding kidney failure to the picture makes these restrictions feel even more urgent. But the evidence behind the advice is weaker than most people assume. A systematic review and meta-analysis found that combining sodium and fluid restriction did not significantly reduce the risk of death or hospitalization in heart failure patients.28PubMed. Are the recommendation of sodium and fluid restriction in heart failure patients changing over the past years? A systematic review and meta-analysis The quality of the evidence was rated low, meaning the studies were not large or rigorous enough to draw confident conclusions either way.
That does not mean patients should ignore salt and fluid entirely. For someone who is visibly overloaded with fluid, restricting intake makes intuitive clinical sense and may reduce symptoms. But for stable patients who are well-managed on medications, extremely tight restrictions may reduce quality of life without measurably extending it. This is an area where a one-size-fits-all rule does more harm than good, and where individual conversations with a care team matter more than blanket advice.